Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
Journal of Medicinal Chemistry
|
March 4, 2021
Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors
Helen E Aylott, Stephen J Atkinson, Paul Bamborough, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 26, 2010
Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine
Paula L Nichols, Jonathan Brand, Michael Briggs, et al.
ACS Medicinal Chemistry Letters
|
August 25, 2020
GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family
Alex Preston, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
July 24, 2020
The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor
Jonathan T Seal, Stephen J Atkinson, Helen Aylott, et al.
Journal of Medicinal Chemistry
|
July 13, 2021
Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors
Jonathan T Seal, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
June 22, 2026
Discovery of an Orally Available Potent ER Aminopeptidase 1 (ERAP1) Inhibitor That Enhances Antitumor Responses and Limits Inflammatory Autoimmunity <i>In Vivo</i>
Christopher P Tinworth, Justyna Wojno-Picon, Michael Adam, et al.
Journal of Medicinal Chemistry
|
November 15, 2022
Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432
Philip G Humphreys, Niall A Anderson, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
April 13, 2026
Automated Molecular Design in BRADSHAW, Applied to the Optimization of ERAP1 Inhibitors
Robert P Law, Ian D Wall, Richard Lonsdale, et al.
Journal of Medicinal Chemistry
|
January 7, 2020
Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening
Christopher R Wellaway, Dominique Amans, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
June 12, 2024
Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787
David J Hirst, Paul Bamborough, Niam Al-Mahdi, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
Journal of Medicinal Chemistry
|
March 4, 2021
Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors
Helen E Aylott, Stephen J Atkinson, Paul Bamborough, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 26, 2010
Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine
Paula L Nichols, Jonathan Brand, Michael Briggs, et al.
ACS Medicinal Chemistry Letters
|
August 25, 2020
GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family
Alex Preston, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
July 24, 2020
The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor
Jonathan T Seal, Stephen J Atkinson, Helen Aylott, et al.
Journal of Medicinal Chemistry
|
July 13, 2021
Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors
Jonathan T Seal, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
June 22, 2026
Discovery of an Orally Available Potent ER Aminopeptidase 1 (ERAP1) Inhibitor That Enhances Antitumor Responses and Limits Inflammatory Autoimmunity <i>In Vivo</i>
Christopher P Tinworth, Justyna Wojno-Picon, Michael Adam, et al.
Journal of Medicinal Chemistry
|
November 15, 2022
Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432
Philip G Humphreys, Niall A Anderson, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
April 13, 2026
Automated Molecular Design in BRADSHAW, Applied to the Optimization of ERAP1 Inhibitors
Robert P Law, Ian D Wall, Richard Lonsdale, et al.
Journal of Medicinal Chemistry
|
January 7, 2020
Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening
Christopher R Wellaway, Dominique Amans, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
June 12, 2024
Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787
David J Hirst, Paul Bamborough, Niam Al-Mahdi, et al.
Page
of 3